The tumour growth advantage was also supported by the upregulation of pAKT1, pMTOR, pRPS6, pEIF4EBP1, MKI67, MYC and HK2 and the downregulation of hsa‐miR‐429 (Figure 6C and Figure S9). The gene discussed is HK2; the disease is neoplasm.